Get the app
US › Healthcare

aTyr Pharma, Inc. (ATYR)

US · Healthcare · Biotechnology

$0.17-5.43%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.3M
EPS
$-0.11
EPS estimate
$-0.15

EPS came in at -0.11 against a street estimate of -0.15 — a beat of 26.7%.

Key statistics

Market cap
$19.7M
Forward P/E
0.0
P/B
0.75
Book value
$0.50
EPS (TTM)
$-0.62
52-week high
$1.11
52-week low
$0.18
50-day MA
$0.43
200-day MA
$0.64
Beta
0.91

Analyst view

Analysts rate aTyr Pharma, Inc. a buy (4 buy, 5 hold, 0 sell out of 9) with an average price target of $2.86.

Shareholding

Insiders
0.31%
Institutions
36.22%

Largest institutional holders

FundStake
Federated Hermes Inc8.68%
Vanguard Capital Management, LLC3.88%
Kalehua Capital Management LLC3.65%
GSA Capital Partners LLP3.52%
AQR Capital Management LLC2.66%
FMR Inc2.52%
BlackRock Inc1.86%
Jane Street Group LLC1.75%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for aTyr Pharma, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.